# Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease

> **NCT00794313** · NA · TERMINATED · sponsor: **Oregon Health and Science University** · enrollment: 3 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Amantadine 300 mg
- **DRUG:** Topiramate
- **DRUG:** Sugar Pill

## Key facts

- **NCT ID:** NCT00794313
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Funding Ended
- **Last updated:** 2018-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00794313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00794313, "Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00794313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*